

June 2026

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Egypt, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 15 years.



## Local expertise, global strength



3

Manufacturing plants



1,000+

Colleagues

## Supporting patients on their health journey

We go beyond the production of medicine by developing disease awareness programmes for various therapeutic areas to support patients in managing their health.

Hikma in Egypt is ranked #9 among the pharmaceutical companies based on sales<sup>1</sup>

Launching 2-3 new oral oncology products annually

## Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

## Manufacturing high-quality medicines

Our three strategically located plants produce a variety medicines in key therapeutic areas:

### Cephalosporin plant

Delivers high-quality anti-infectives

### General formulation plant

Manufactures a wide range of medicines in various dosage forms

### Oncology/ Immunosuppressant plant

Dedicated to producing essential cancer treatments with the first immunosuppressant production capabilities in Egypt

## A diversified portfolio of medicines

We offer the Egyptian patient over 158 medicines covering 12 therapeutic areas addressing a wide range of healthcare needs:



Oncology



Diabetes



Gastrointestinal



Cardiovascular



Anti-infectives



Others

Hikma's oral oncology plant with a dedicated immunosuppressant production area is the first in Egypt

Ranked #2 in oral-systemic, oral anti-infectives<sup>2</sup>

Hikma has a 2.54% market share of the total Egyptian pharmaceutical market<sup>1</sup>

#### Reference:

1. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA Monthly MIDAS M03 2026 data publication, for the Rolling 12 Months data as MAT Mar. 2026, reflecting the estimates of real-world activity. Copyright IQVIA. All rights reserved.

\*\*MENA Region includes 9 Countries - \*Algeria, Egypt, \*Jordan, Kuwait, \*Lebanon, \*Morocco, Saudi Arabia, Tunisia & UAE.

\*Countries - Countries in MENA Region Marked with \*\* are markets constituting of Retail Channel Data only.

Note - All claims are based on the Metric - Value Sales (in USD) only. All Ranks & Market Share percentages have been calculated using the same metric.

2. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period .MAT Aug. 2024, Market definitions: Oral Systemic and Oral Anti-infectives market - ATC3 J1A, J1b, J1C, J1D, J1E, J1F, J1G, J1H, J1M, J1X, J2A, J4A, J4B, J5B, J5C, J5D, J7E & J7X and NFC123 AAA, AAG, AAK, ABA, ABC, ACA, ACY, BAA, BBC, BCA, DEP, DGB, DGI, DGK, DGM & DGN reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

#### Company information

Vice President - Egypt & Sudan:  
Tamer Jardaneh

#### Hikma Pharmaceuticals - Egypt

Giza - 6<sup>th</sup> of October - Second Industrial Area - Plot #1

#### Contacts

See [www.hikma.com](http://www.hikma.com) for contact forms